An international serum standard for application in assays to detect human complement activation products.
about
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesInflammatory Response After Laparoscopic Versus Open Resection of Colorectal Liver Metastases: Data From the Oslo-CoMet TrialComplement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples.Seventy-two hours of mild hypothermia after cardiac arrest is associated with a lowered inflammatory response during rewarming in a prospective observational studyEculizumab in Pediatric Dense Deposit Disease.Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases.The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis.Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis.Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.Cyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation.Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease.The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.The alternative complement pathway is dysregulated in patients with chronic heart failureCombined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis.Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsisComplement factors C4 and C3 are down regulated in response to short term overfeeding in healthy young men.Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome.Immunogenicity/hypersensitivity of biologics.Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome.Gain of function mutant of complement factor B K323E mimics pathogenic C3NeF autoantibodies in convertase assays.Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.Reduced order modeling and analysis of the human complement system.Cytokine responses, microbial aetiology and short-term outcome in community-acquired pneumonia.Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock.Complement C4d-specific antibodies for the diagnosis of lung cancer.Systemic inflammation in acute intermittent porphyria: a case-control study.Serial multiple crossed immunoelectrophoresis at a microscale: A stamp-sized 2D immunoanalysis of protein C3 activation caused by nanoparticles.Inhibition of Immune Complex Complement Activation and Neutrophil Extracellular Trap Formation by Peptide Inhibitor of Complement C1.Combined Inhibition of C5 and CD14 Attenuates Systemic Inflammation in a Piglet Model of Meconium Aspiration Syndrome.A novel method for direct measurement of complement convertases activity in human serum.The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction
P2860
Q26766424-4A3280B2-F90A-4C7F-ACFA-8676468667A2Q31010163-8663015A-46D0-46E2-A91C-926C630AC968Q33416830-614CE6B4-079E-4A7C-8483-59B08B436F1DQ33568131-B3022F1A-8630-46E0-B39B-5DD79080DBE3Q34402332-F4C51096-9F9D-4882-84EE-3813D0235593Q36123605-C5A2F2DF-830D-47B0-BF14-AF57C1F37B06Q36330303-5B6F35BD-42DA-442D-91F1-5733F9C76F8EQ37315643-6BC6C1B1-87EE-40B7-A293-B6E8311FBD8CQ37423983-2A5B0383-570F-4292-8EC2-12C2ECC75BABQ37547496-5C2B020E-ACCD-4022-B99B-D7136782D06CQ38601679-ECB5D322-4982-46E8-BF09-C67953F48FDBQ38657043-CDDFFA5F-76A3-450B-9288-F1529E9F0973Q38907049-A1AEAE0F-A68C-4C00-97B9-0465D9FBB977Q39003418-CF134330-D597-4597-808C-A1F2A57E122AQ39014623-DBF07B88-8FB0-4E80-997E-D078756A79B6Q40333926-E7DCFBF1-B98D-441F-90A2-7BF5E524A74AQ40892746-B7524E50-33B2-43B8-9DE1-BDE14CC92085Q41293387-E275AEEF-214F-4207-8093-D9D19DD33666Q42268451-94B06C86-D724-4150-A4A7-16CCB2377F14Q42425232-BAB54BB4-BBE5-45C5-8D86-045B16B78B8AQ42674523-3BB744B3-F730-4E70-983E-212E4BBAB12DQ43844720-043E85B4-7A09-43FE-AC79-093541D251E1Q46246159-9311AC37-781F-4F0B-BC10-EA3C9A9BB903Q47225530-53A0553D-70B4-433F-9F7B-FDCB826C1B25Q47327397-3703686F-962F-4DA5-B391-738B22EB4375Q47331810-7FCF9C54-F8FE-40DB-B621-3E6B1544C3F7Q48240599-57818A0D-EC95-4722-85F9-403D5EEB9803Q48500144-68BD0EAC-F6DC-4407-8CC0-2E6B3FC37B43Q49787484-AA75DA23-2B2F-469E-96AF-8A137DE10BB8Q51320785-C67A3CCD-57D5-4ACD-B4F3-5FB13D62E956Q51657582-1370C779-CA6F-4118-ACDD-FBD78B5D5FB8Q52327307-E56D8795-B56F-4B02-BE57-2C4205C7C82FQ52372103-9FA74F1F-BD17-476B-8B62-D1B4BC48EFE3Q53842724-34E8BFA1-1267-4FC4-8082-C20E18FA5242Q55147541-36F1706D-6DE2-4DD4-B092-0B12EF1A4FEAQ58746571-B63549BF-39EC-4EB5-8714-B583F9FB1B55
P2860
An international serum standard for application in assays to detect human complement activation products.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
An international serum standar ...... omplement activation products.
@en
type
label
An international serum standar ...... omplement activation products.
@en
prefLabel
An international serum standar ...... omplement activation products.
@en
P2093
P1433
P1476
An international serum standar ...... omplement activation products.
@en
P2093
Grethe Bergseth
Judith K Ludviksen
Michael Kirschfink
Patricia C Giclas
P304
P356
10.1016/J.MOLIMM.2013.05.221
P577
2013-06-17T00:00:00Z